​

Sonnet BioTherapeutics (SONN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

SONN Stock Rating

Sonnet BioTherapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

SONN Price Target Upside V Benchmarks

TypeNameUpside
StockSonnet BioTherapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.18$1.18$1.18
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-1---1
May, 25-1---1
Apr, 25-1---1
Mar, 25-1---1
Feb, 25-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 19, 2023Chardan CapitalBuyBuyhold
Sep 15, 2021BTIGBuyinitialise

Financial Forecast

EPS Forecast

$-2K $-1K $-900 $-600 $-300 $0 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27
Reported$-150.79$-18.14----
Avg Forecast$-1.18K$-166.18$-12.88$-3.42$-98.56$-96.80
High Forecast$-1.18K$-166.18$-12.88$-3.42$-98.56$-96.80
Low Forecast$-1.18K$-166.18$-12.88$-3.42$-98.56$-96.80
Surprise %-87.17%-89.08%----

Revenue Forecast

$0 $80K $160K $240K $320K $400K Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27
Reported$349.94K$147.81K----
Avg Forecast$400.00K$83.33K$50.00K$10.58K$6.01K$3.41K
High Forecast$400.00K$83.33K$50.00K$10.58K$6.01K$3.41K
Low Forecast$400.00K$83.33K$50.00K$10.58K$6.01K$3.41K
Surprise %-12.51%77.37%----

Net Income Forecast

$-2B $-1B $-900M $-600M $-300M $0 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27
Reported$-29.77M$-18.83M----
Avg Forecast$-1.22B$-108.89M$-8.44M$-2.24M$-64.58M$-63.43M
High Forecast$-1.22B$-108.89M$-8.44M$-2.24M$-64.58M$-63.43M
Low Forecast$-1.22B$-108.89M$-8.44M$-2.24M$-64.58M$-63.43M
Surprise %-97.56%-82.70%----

SONN Forecast FAQ

Is Sonnet BioTherapeutics stock a buy?

Sonnet BioTherapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Sonnet BioTherapeutics is a favorable investment for most analysts.

What is Sonnet BioTherapeutics's price target?

Sonnet BioTherapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.18.

How does Sonnet BioTherapeutics stock forecast compare to its benchmarks?

Sonnet BioTherapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Sonnet BioTherapeutics over the past three months?

  • June 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Sonnet BioTherapeutics’s EPS forecast?

Sonnet BioTherapeutics's average annual EPS forecast for its fiscal year ending in September 2024 is $-12.88, marking a -29.00% decrease from the reported $-18.14 in 2023. Estimates for the following years are $-3.42 in 2025, $-98.56 in 2026, and $-96.8 in 2027.

What is Sonnet BioTherapeutics’s revenue forecast?

Sonnet BioTherapeutics's average annual revenue forecast for its fiscal year ending in September 2024 is $50K, reflecting a -66.17% decrease from the reported $147.8K in 2023. The forecast for 2025 is $10.58K, followed by $6.01K for 2026, and $3.41K for 2027.

What is Sonnet BioTherapeutics’s net income forecast?

Sonnet BioTherapeutics's net income forecast for the fiscal year ending in September 2024 stands at $-8.44M, representing a -55.19% decrease from the reported $-18.833M in 2023. Projections indicate $-2.241M in 2025, $-64.581M in 2026, and $-63.427M in 2027.